The most common grade 3 or worse adverse events for patients treated with vorinostat were fatigue or malaise ( 51 [ 16 % ] patients in the vorinostat group vs 25 [ 8 % ] in the placebo group ] ) and dyspnoea ( 35 [ 11 % ] vs 45 [ 14 % ] ) .